亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

医学 跨国公司 药品 比例(比率) 内科学 第一行 药理学 业务 地理 地图学 财务
作者
Marc A. Suchard,Martijn J. Schuemie,Harlan M. Krumholz,Seng Chan You,Ruijun Chen,Nicole Pratt,Christian Reich,Jon Duke,David Madigan,George Hripcsak,Patrick Ryan
出处
期刊:The Lancet [Elsevier BV]
卷期号:394 (10211): 1816-1826 被引量:378
标识
DOI:10.1016/s0140-6736(19)32317-7
摘要

Background Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice. Methods We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias. Using this framework, we did a systematic, large-scale study under a new-user cohort design to estimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six secondary effectiveness and 46 safety outcomes comparing all first-line classes across a global network of six administrative claims and three electronic health record databases. The framework addressed residual confounding, publication bias, and p-hacking using large-scale propensity adjustment, a large set of control outcomes, and full disclosure of hypotheses tested. Findings Using 4·9 million patients, we generated 22 000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75–0·95), hospitalisation for heart failure (0·83, 0·74–0·95), and stroke (0·83, 0·74–0·95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes. Interpretation This comprehensive framework introduces a new way of doing observational health-care science at scale. The approach supports equivalence between drug classes for initiating monotherapy for hypertension—in keeping with current guidelines, with the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-dihydropyridine calcium channel blockers. Funding US National Science Foundation, US National Institutes of Health, Janssen Research & Development, IQVIA, South Korean Ministry of Health & Welfare, Australian National Health and Medical Research Council.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老顽童完成签到 ,获得积分10
刚刚
zsm完成签到 ,获得积分10
2秒前
WQ完成签到,获得积分10
3秒前
Fin2046完成签到,获得积分10
5秒前
5秒前
所所的应助被科研通管家采纳,获得10
6秒前
科研通AI65的应助被科研通管家采纳,获得10
6秒前
FashionBoy的应助被科研通管家采纳,获得10
6秒前
6秒前
Akim的应助被科研通管家采纳,获得10
6秒前
李健的应助被科研通管家采纳,获得10
6秒前
脑洞疼的应助被科研通管家采纳,获得10
6秒前
Dr.Joseph完成签到,获得积分10
8秒前
zsm关注了科研通微信公众号
10秒前
magic完成签到,获得积分10
14秒前
diyyid完成签到,获得积分10
15秒前
15秒前
千仞发布了新的文献求助10
18秒前
BIBIYU完成签到,获得积分10
20秒前
润run发布了新的文献求助10
21秒前
段棋晔发布了新的文献求助10
22秒前
24秒前
挚友发布了新的文献求助10
24秒前
Hello的应助被机智的青易采纳,获得10
25秒前
精明尔柳完成签到,获得积分10
26秒前
szxa发布了新的文献求助10
27秒前
27秒前
29秒前
once发布了新的文献求助30
30秒前
30秒前
充电宝的应助被刻苦乐天采纳,获得10
30秒前
30秒前
31秒前
永日安宁完成签到,获得积分10
33秒前
傅jh发布了新的文献求助10
33秒前
kali发布了新的文献求助10
36秒前
丘比特的应助被moriaty采纳,获得20
37秒前
38秒前
研友_VZG7GZ的应助被dyler采纳,获得10
38秒前
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184932
求助须知:如何正确求助?哪些是违规求助? 9573870
关于积分的说明 21833572
捐赠科研通 7782362
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558650
邀请新用户注册赠送积分活动 2481161